InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
67,035.34
(
-0.20%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: TheFinalCD post# 245010

Monday, 01/09/2023 8:48:46 AM

Monday, January 09, 2023 8:48:46 AM

Post# of 252642
re: APGN

Looks interesting. Up 80% inn pre-Market


EF Hutton analyst Tony Butler initiated coverage of Apexigen with a Buy rating and $8 price target. The "recently de-SPACed" biotech is developing sotigalimab as an orthogonal immunoactivating therapy in combination with immune checkpoint inhibitors and chemotherapy against a number of cancer indications, Butler tells investors.

Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up